SCHEMBL624765

SCHEMBL624765

O=C(c1n[nH]c2ccccc12)N1CCN(c2cc(OC3CCC3)ncn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
RBP4 P02753 1/20 0.46
DRD2 P14416 1/20 0.45
DRD3 P35462 1/20 0.45
LMNA P02545 3/20 0.45
TSHR P16473 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.42
FLT3 P36888 2/20 0.42
HPGD P15428 2/20 0.42
GRM5 P41594 1/20 0.42
ACACB O00763 2/20 0.42
EIF4A3 P38919 1/20 0.41
LRRK2 Q5S007 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622195 0.88 RBP4 (0.49) RBP4TSHRACACBLRRK2AHR
SCHEMBL624545 0.82 RBP4 (0.49) ALDH1A1MAPTRBP4DRD2DRD3
SCHEMBL623147 0.82 ALDH1A1 (0.52) ALDH1A1MAPTDRD2DRD3LMNA
SCHEMBL624623 0.81 DRD2 (0.49) ALDH1A1MAPTRBP4DRD2TSHR
SCHEMBL624118 0.80 TP53 (0.44) ALDH1A1MAPTLMNAKMT2AHTT
SCHEMBL624230 0.78 PDE2A (0.46) LMNATSHRMEN1KMT2AACACB
SCHEMBL623285 0.77 ACACB (0.45) MEN1KMT2AACACB
SCHEMBL623470 0.76 ALOX15 (0.45) ALDH1A1LMNATSHRMEN1KMT2A
SCHEMBL623169 0.76 TSHR (0.53) ALDH1A1TSHRGAAACACBKDM4E
SCHEMBL623906 0.76 PTK2 (0.54) TSHRGRM5ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ALDH1A1 2071/4885MAPT 3432/4885RBP4 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.